Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Shares IssuedShares OutstandingShares Outstanding
Ratios

Nuvectis Pharma (NVCT) Shares Issued (2022 - 2026)

Nuvectis Pharma has reported Shares Issued over the past 5 years, most recently at $7000.0 for Q1 2026.

  • Quarterly results put Shares Issued at $7000.0 for Q1 2026, down 99.45% from a year ago — trailing twelve months through Mar 2026 was $14.1 million (up 67.42% YoY), and the annual figure for FY2025 was $15.5 million, up 28.99%.
  • Shares Issued reached $7000.0 in Q1 2026 per NVCT's latest filing, down from $13.5 million in the prior quarter.
  • Across five years, Shares Issued topped out at $16.0 million in Q1 2022 and bottomed at -$121000.0 in Q3 2022.
  • Median Shares Issued over the past 5 years was $1.4 million (2024), compared with a mean of $3.9 million.
  • The largest annual shift saw Shares Issued surged 10614.29% in 2024 before it tumbled 99.45% in 2026.
  • Over 5 years, Shares Issued stood at $121000.0 in 2022, then plummeted by 88.43% to $14000.0 in 2023, then surged by 28135.71% to $4.0 million in 2024, then skyrocketed by 241.51% to $13.5 million in 2025, then tumbled by 99.95% to $7000.0 in 2026.
  • Business Quant data shows Shares Issued for NVCT at $7000.0 in Q1 2026, $13.5 million in Q3 2025, and $600000.0 in Q2 2025.